Meaningful progress in establishing causative genetic mutations and environmental factors implicated in ALS disease progression and advances in validating emerging biomarkers to evaluate treatment response has meant that the landscape for drug development in ALS is exploding. With exciting new targets, revised inclusion criteria, and opportunities to implement digital biomarkers for remote and sensitive monitoring, we have never been closer to bringing meaningful therapies to patients.
Uniting industry experts dedicated to accelerating effective therapeutic approaches, the ALS Drug Development Summit is the definitive industry forum sharing cross-industry insight to rapidly advance life-changing ALS therapeutics.
From dissecting exciting progress in small molecules and gene therapy to clarifying sensitive primary outcome measures beyond ALSFRS-R, join industry experts from Biogen, Eli Lilly, Mitsubishi Tanabe Pharma, Sanofi, ProMIS Neurosciences, Cytokinetics, Brainstorm Cell Therapeutics and many more to drive progress towards slowed disease progression and improved outcomes in ALS.
Drug Developer - Conference + 2 Workshops: USD 3497.0,
Drug Developer - Conference + 1 Workshop: USD 3048.0,
Drug Developer - Conference Only: USD 2599.0,
Solution Provider - Conference + 2 Workshops: USD 4297.0,
Solution Provider - Conference + 1 Workshop: USD 3748.0,
Solution Provider - Conference Only: USD 3199.0,
Academic - Conference + 2 Workshops: USD 2897.0,
Academic - Conference + 1 Workshop: USD 2548.0,
Academic - Conference Only: USD 2199.0
Speakers: Amir Lahav, Head of Digital R and D, Digital Healthcare Innovation, Mitsubishi Tanabe Pharma Holdings America, Andrew Wolff, Senior Vice President, Senior Fellow, Clinical Research and Development, Cytokinetics, Angela Genge, Chief Medical Officer, QurAlis, Dimitry Ofengeim, Head of Precision Neurology and Neuroinflammation Cluster, Sanofi, Ferenc Tracik, Chief Medical Officer, NeuroSense Therapeutics, James Berry, Chief, Division of ALS and Motor Neuron Diseases, Massachusetts General Hospital, Jeremy Shefner, Professor and Chair of Neurology, Barrow Neurological Institute, Johanne Kaplan, Chief Development Officer, ProMIS Neurosciences, Kasper Roet, Founder and Chief Executive Officer, QurAlis, Leonard van den Berg, Professor of Neurology, University Medical Center Utrecht, Mansuo Hayashi, Chief Scientific Officer, Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, Merit Cudkowicz, Chief of Neurology, Massachusetts General Hospital, Michael Benatar, Professor of Neurology, University of Miami, Miroslaw Brys, Senior Director, Neurodegeneration Clinical Head, Eli Lilly and Company, Neil Cashman, Chief Scientific Officer and Co-founder, ProMIS Neurosciences, Olivier Hermine, Chief Scientific Officer, AB Science, Peter Vanderklish, Chief Scientific Officer, Spinogenix, Ralph Kern, President and Chief Medical Officer, Brainstorm Cell Therapeutics, Robert Bowser, Chief Scientific Officer, Professor and Chair of Translational Neuroscience, Barrow Neurological Institute, Robert Scannevin, Chief Scientific Officer, Verge Genomics, Stacy Rudnicki, Vice President, Clinical Research, Cytokinetics, Stephanie Fradette, Senior Medical Director, Clinical Development, Biogen, Thomas Holm, Pedersen Chief Executive Officer, NMD Pharma, Kelley Erb, Director, Digital and Quantitative Medicine, Biogen
Time: 09:00 - 16:30